{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:59Z","timestamp":1707524459083},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,23]]},"DOI":"10.7759\/cureus.21532","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T04:24:22Z","timestamp":1642998262000},"source":"Crossref","is-referenced-by-count":0,"title":["Hyperprolactinemia in Adults Treated With Anti-psychotic Drugs Attending Tertiary Hospitals in Oman: An Observational Study"],"prefix":"10.7759","author":[{"given":"Mohamed S","family":"Al Harthi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamra S","family":"Al Ghafri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loai","family":"Al Wasify","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Al Akhzami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"AlHarthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saud","family":"Al Harthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser","family":"Al Sibani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-1208.121400","article-title":"Hyperprolactinemia","volume":"6","author":"Majumdar A","year":"2013","unstructured":"Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013, 6:168-75. 10.4103\/0974-1208.121400","journal-title":"J Hum Reprod Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2174\/1871530317666170424102332","article-title":"Hyperprolactinemia induced by antipsychotics: from diagnosis to treatment approach","volume":"17","author":"Milano W","year":"2017","unstructured":"Milano W, Colletti C, Capasso A. Hyperprolactinemia induced by antipsychotics: from diagnosis to treatment approach. Endocr Metab Immune Disord Drug Targets. 2017, 17:38-55. 10.2174\/1871530317666170424102332","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4730-6","article-title":"Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research","volume":"234","author":"Grigg J","year":"2017","unstructured":"Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl). 2017, 234:3279-97. 10.1007\/s00213-017-4730-6","journal-title":"Psychopharmacology (Berl)"},{"key":"ref4","unstructured":"Saloni Dattani HRaMR. Mental health. Our World in Data. (2021). https:\/\/www.futurelearn.com\/info\/blog\/world-mental-health-day."},{"key":"ref5","article-title":"Antipsychotic medicines for treating schizophrenia and bipolar disorder: a review of the research for adults and caregivers","author":"John M. Eisenberg Center for Clinical Decisions and Communications Science","year":"2013","unstructured":"John M. Eisenberg Center for Clinical Decisions and Communications Science. Antipsychotic medicines for treating schizophrenia and bipolar disorder: a review of the research for adults and caregivers. Comparative Effectiveness Review Summary Guides for Consumers. Agency for Healthcare Research and Quality, Rockville; 2013."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3109\/00048674.2011.589044","article-title":"Antipsychotic-induced hyperprolactinaemia","volume":"45","author":"Inder WJ","year":"2011","unstructured":"Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry. 2011, 45:830-7. 10.3109\/00048674.2011.589044","journal-title":"Aust N Z J Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman ME","year":"2000","unstructured":"Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000, 80:1523-631. 10.1152\/physrev.2000.80.4.1523","journal-title":"Physiol Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.203118","article-title":"Asymmetric, tender gynecomastia induced by olanzapine in a young male","volume":"39","author":"Shahi MK","year":"2017","unstructured":"Shahi MK, Kar SK, Singh A. Asymmetric, tender gynecomastia induced by olanzapine in a young male. Indian J Psychol Med. 2017, 39:215-6. 10.4103\/0253-7176.203118","journal-title":"Indian J Psychol Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed S","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96:273-88. 10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders: Recent Developments and Current Perspectives","volume":"27","author":"Byerly M","year":"2007","unstructured":"Byerly M, Suppes T, Tran Q-V, Baker RA. Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders: Recent Developments and Current Perspectives. Journal of Clinical Psychopharmacology. 2007, 27:","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.3.199","article-title":"Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review","volume":"182","author":"Wieck A","year":"2003","unstructured":"Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry. 2003, 182:199-204. 10.1192\/bjp.182.3.199","journal-title":"Br J Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad PM","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004, 64:2291-314. 10.2165\/00003495-200464200-00003","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.109941","article-title":"Antipsychotic-induced hyperprolactinemia in aging populations: prevalence, implications, prevention and management","volume":"101","author":"Gonz\u00e1lez-Rodr\u00edguez A","year":"2020","unstructured":"Gonz\u00e1lez-Rodr\u00edguez A, Labad J, Seeman MV. Antipsychotic-induced hyperprolactinemia in aging populations: prevalence, implications, prevention and management. Prog Neuropsychopharmacol Biol Psychiatry. 2020, 101:109941. 10.1016\/j.pnpbp.2020.109941","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/159402","article-title":"Hyperprolactinemia with antipsychotic drugs in children and adolescents","volume":"2010","author":"Rosenbloom AL","year":"2010","unstructured":"Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol. 2010, 2010:10.1155\/2010\/159402","journal-title":"Int J Pediatr Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.02.014","article-title":"Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia","volume":"34","author":"Yasui-Furukori N","year":"2010","unstructured":"Yasui-Furukori N, Saito M, Nakagami T, et al.. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34:537-40. 10.1016\/j.pnpbp.2010.02.014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon BJ","year":"2003","unstructured":"Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003, 28:55-68. 10.1016\/s0306-4530(02)00127-0","journal-title":"Psychoneuroendocrinology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.11.21256928","article-title":"Prevalence of macroprolactin in hyperprolactinemic patients receiving anti-psychotics","author":"Al Wasify LA","year":"2021","unstructured":"Al Wasify LA, Al Maamary SS, Al Tobi MN. Prevalence of macroprolactin in hyperprolactinemic patients receiving anti-psychotics. medRxiv. 2021, 10.1101\/2021.05.11.21256928","journal-title":"medRxiv"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228648","article-title":"Prolactin response to antipsychotics: an inpatient study","volume":"15","author":"Dehelean L","year":"2020","unstructured":"Dehelean L, Romosan AM, Papava I, Bredicean CA, Dumitrascu V, Ursoniu S, Romosan RS. Prolactin response to antipsychotics: an inpatient study. PLoS One. 2020, 15:e0228648. 10.1371\/journal.pone.0228648","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2013.08.008","article-title":"Psychotropic-induced hyperprolactinemia: a clinical review","volume":"55","author":"Ajmal A","year":"2014","unstructured":"Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014, 55:29-36. 10.1016\/j.psym.2013.08.008","journal-title":"Psychosomatics"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03814.x","article-title":"Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management","volume":"74","author":"Holt RI","year":"2011","unstructured":"Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 2011, 74:141-7. 10.1111\/j.1365-2265.2010.03814.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107086516","article-title":"Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder","volume":"22","author":"Walters J","year":"2008","unstructured":"Walters J, Jones I. Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol. 2008, 22:82-9. 10.1177\/0269881107086516","journal-title":"J Psychopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107087373","article-title":"Current guidelines and their recommendations for prolactin monitoring in psychosis","volume":"22","author":"Citrome L","year":"2008","unstructured":"Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol. 2008, 22:90-7. 10.1177\/0269881107087373","journal-title":"J Psychopharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1192\/apt.bp.115.014928","article-title":"Management of antipsychotic-induced hyperprolactinaemia","volume":"23","author":"Gupta S","year":"2018","unstructured":"Gupta S, Lakshmanan DA, Khastgir U, Nair R. Management of antipsychotic-induced hyperprolactinaemia. BJPsych Adv. 2018, 23:278-86. 10.1192\/apt.bp.115.014928","journal-title":"BJPsych Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/74677-hyperprolactinemia-in-adults-treated-with-anti-psychotic-drugs-attending-tertiary-hospitals-in-oman-an-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:37Z","timestamp":1707507817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/74677-hyperprolactinemia-in-adults-treated-with-anti-psychotic-drugs-attending-tertiary-hospitals-in-oman-an-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,23]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.21532","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,23]]}}}